Novartis hands investors Alcon spin-off and $5 billion share buyback

ZURICH (Reuters) – Novartis plans to spin off its Alcon eye care business to shareholders and repurchase up to $5 billion in shares, as Chief Executive Vas Narasimhan refocuses the Swiss firm on prescription drugs.

…read more

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Source:: Reuters – Business News